UTILIZATION OF PROTON PUMP INHIBITORS AND PROMOTING THE QUALITY USE FOR ASSESSMENT.

PPIs irreversibly inhibit the gastric H+-ATPase pump also known as proton pump and reduce both basal and stimulated gastric output. Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-esophageal reflux. They accumulate in the target cell and are activated by acid and bind strongly to the specific target - the proton pump, inappropriate PPI use results in increased healthcare costs and unnecessary exposure to potential adverse effects. Ideally, PPI therapy should be personalized, based on indication, effectiveness, patient preference, and risk assessment.